Parliament has adopted its second interim report on Hungary’s persistent undermining of the rule of law and its continuous breaches of EU values.Committee on Civil Liberties, Justice and Home Affairs Source : © European…
Reaching milestone in orthobiologics sales.
Increasing sales, improved coverage ratio and lowered break-even.
Today, Crunchfish AB (“Crunchfish”) publishes the company’s interim report for the first quarter of 2024. Below is a brief summary of the report..
We have successfully entered a new era as a pure play orthobiologics company.
Increased EBITDA and positive cash flow.
Lower sales but increased margins during the quarter.
Strong cash position providing optionality.
Increased margins and positive cash flow during the quarter.
Opening remarks During the second quarter of the fiscal year, Hamlet Pharma has made significant progress in its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bl…
Sales increase, in a quarter without restrictions.
Growth with increased margins during the quarter.
”During the second quarter we have continued to grow our industrial group. So far in 2022, we have acquired eight new companies. Since the start, a little over a year ago, we have completed 19 acquisitions and the group…
Turbulent quarter with several bright spots.
Nyheter om Interim Report som RSS
Nya nyheter om ämnet laddas automatiskt ner till din nyhetsläsare. Du får gärna publicera eller länka till flödet. Fler RSS-flöden